In situ coagulation environment regulation-assisted thrombus clearance via hydrogenated silicon-based nanothrombolytics.
Ya-Xuan Zhu, Zhixin Chen, Yanling You, Yihan Chen, Wenjie Yu, Xue Guan, Piao Zhu, Jie Yang, Min Ge, Xiaojun Chen, Han Lin, Jianlin Shi · Science advances · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In a laboratory model, first, the therapeutic safety could be ensured through the reversible activity locking of the loaded thrombolytic agent, UK, via the interaction between the enzyme and SiH surface. These findings from a laboratory model add evidence supporting molecular hydrogen's biological and therapeutic potential in the model studied.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen was evaluated in this publication and summarizes the source-grounded findings below. First, the therapeutic safety could be ensured through the reversible activity locking of the loaded thrombolytic agent, UK, via the interaction between the enzyme and SiH surface.
What the Researchers Studied
The study used a in vitro cell-culture laboratory experiment.
What Effects Did Molecular Hydrogen Have?
Rabbit anti–glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was purchased from Boster Biological Technology Co. To evaluate the hydrogen generation property, SiH or SiH@UK/Fib NSs were first dispersed in deionized water at a Si concentration of 2 mg/ml. First, the therapeutic safety could be ensured through the reversible activity locking of the loaded thrombolytic agent, UK, via the interaction between the enzyme and SiH surface. Functionally, SiH nanosheet plays multiple roles in the nanothrombolytics: blocking the functional sites of urokinase to durably inhibit its activity in circulation to prevent systemic bleeding, followed by urokinase reactivation in response to SiH nanosheet self-degradation and prothrombotic microenvironment regulation through the in situ hydrogen generation, which mitigates the oxidative stress of vascular endothelial cells and inhibits their release of procoagulant factors. Thrombolysis activity regulation and hydrogen generation mechanisms of SiH@UK/Fib. ( A ) Molecular docking simulation results of the interaction between UK and SiH. ( B ) Time-related activity changes of SiH@UK/Fib indicated by the chromogenic reaction of S-2444. a.u., arbitrary units. ( C ) Hydrogen generation of SiH@UK/Fib in PBS measured by gas chromatography. ( D ) Heatmap indicating the time-dependent FTIR absorbance changes of SiH. ( E ) In situ FTIR spectra at different time points. ( F ) Time-dependent profiles of different characteristic peak areas. ( G ) Representative photograph of blood clots treated with PBS buffer (pH 7.4) only, UK, and SiH@UK/Fib for different time periods. h, hours.
Why These Findings Matter
These findings from a laboratory model add evidence supporting molecular hydrogen's biological and therapeutic potential in the model studied.
How Strong Is This Evidence?
This is laboratory evidence from a in vitro cell-culture laboratory experiment. It is most informative for the biological mechanisms, cellular responses, or biochemical outcomes directly measured.
Technical Study Details
H2HUBB classifies this publication as laboratory study with laboratory or cellular evidence. The study used a in vitro cell-culture laboratory experiment.
Limitations and Safety
Reported limitations: Thrombotic disorders remain among the leading causes of global mortality, yet current thrombolytic therapies are limited by poor targeting specificity and inadequate microenvironmental modulation, resulting in suboptimal efficacy and serious side effects.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.